• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Editor’s Choice

Editor's Choice

Microbiome Drug Development: 2022 in Review

December 30, 2022 Luis Gosálbez

Leveraging a year of important research updates, funding rounds, and academic papers, this report compiles the most significant industry news pertaining to microbiome drug development in 2022. It finds that the regulatory approval of three […]

Editor's Choice

Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals

December 22, 2022 Microbiome Times
Editor's Choice

FDA Approves First Fecal Microbiota Product

December 1, 2022 Microbiome Times

Today, the U.S. Food and Drug Administration approved Rebyota, the first fecal microbiota product approved by the agency. Rebyota is approved for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years […]

Editor's Choice

Proge Farm claims Europe’s first regulatory approval for a microbiome-based therapeutic

November 29, 2022 Microbiome Times

Proge Farm, an Italian pharmaceutical company, has made microbiome history with its recently approved therapeutic and will now be able to market its drug based on Lactobaccilus plantarum P 17630. The company obtained authorization from […]

Editor's Choice

Seres Therapeutics Announces FDA acceptance of Biologics License Application For Ser-109

October 28, 2022 Microbiome Times

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for investigational oral microbiome therapeutic SER-109 for […]

Editor's Choice

A microbiome therapeutic is closer than ever to market authorization in the US. What does it mean for the industry?

September 28, 2022 Kristina Campbell

Ferring Pharmaceuticals, Inc. has edged ahead in the race to bring the first microbiome-based drug to market in the United States, with its product REBYOTA receiving the thumbs up from the FDA’s Vaccines and Related […]

Editor's Choice

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

September 23, 2022 Microbiome Times

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential […]

Editor's Choice

Stanford researchers construct most complex, complete synthetic microbiome

September 9, 2022 Microbiome Times

Key studies in the last decade have shown that the gut microbiome, the collection of hundreds of bacterial species that live in the human digestive system, influences neural development, response to cancer immunotherapies, and other […]

Editor's Choice

Fecal Microbiota Transplantation (FMT): Global Industry and Regulatory Overview

June 27, 2022 Luis Gosálbez

First described in the 4th Century in China, practiced since the 1950’s and re-discovered relatively recently [1][2], Fecal Microbiota Transplantation (FMT) or simply Fecal Transplant is a therapeutic approach in which more or less processed […]

Editor's Choice

Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers

April 15, 2022 Laurence Zitvogel

 

Editor's Choice

Did you miss Probiota Copenhagen 2022? Catch up now!

April 12, 2022 Nina Vinot

With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]

Posts navigation

« 1 … 4 5 6 … 14 »

Sign Up to Free Newsletter

QIAGEN WEBINAR SERIES – REGISTER HERE

NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

Editor’s Choice

  • LACTIN-V: A Promising Live Biotherapeutic for Recurrent Bacterial Vaginosis
    May 1, 2026
  • Lactic Acid’s Untapped Potential to Optimise the Vaginal Microbiota and Mucosal Environment
    April 8, 2026
  • Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
    March 24, 2026
  • Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
    February 11, 2026
  • Immunity as a Lifestyle Priority
    January 30, 2026
sign up

Sign up to the Microbiome Times newsletter